Get the Stockscreener App
138.63
1.19%
-1.91
Iqvia Holdings Inc stock is traded at $138.63, with a volume of 922.45K.
It is down -1.19% in the last 24 hours and down -7.50% over the past month.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
See More
Previous Close:
$140.54
Open:
$140.1
24h Volume:
922.45K
Relative Volume:
0.44
Market Cap:
$24.01B
Revenue:
$15.50B
Net Income/Loss:
$1.33B
P/E Ratio:
18.89
EPS:
7.34
Net Cash Flow:
$2.16B
1W Performance:
+1.15%
1M Performance:
-7.50%
6M Performance:
-31.06%
1Y Performance:
-38.75%
1-Day Range:
$138.20
$140.87
1-Week Range:
$134.65
$141.95
52-Week Range:
$134.65
$252.88
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
138.79 | 23.75B | 15.50B | 1.33B | 2.16B | 7.34 |
|
TMO
Thermo Fisher Scientific Inc
|
402.19 | 156.19B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.65 | 141.54B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
514.97 | 41.59B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.11 | 32.35B | 6.53B | 1.26B | 1.31B | 4.35 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf - marketscreener.com
IQV Collaborates with Rein Therapeutics on New IPF Trial | IQV S - GuruFocus
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - marketscreener.com
IQVIA’s SWOT analysis: healthcare data giant faces industry headwinds - Investing.com Australia
IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? - MSN
IQVIA (IQV) Projects Global Cancer Drug Spending to Hit $441B by 2029 - GuruFocus
(IQV) Trading Advice - news.stocktradersdaily.com
IQV: Cautious Outlook Amidst Delayed Decisions | IQV Stock News - GuruFocus
IQVIA Holdings Inc (IQV) Stock Price Down 3.4% on May 21 - GuruFocus
IQVIA Stock: Is Wall Street Bullish Or Bearish? - Barchart.com
IQVIA (IQV) Stock Sees Analyst Target Price Adjustment by JP Mor - GuruFocus
IQVIA (IQV) Stock Sees Analyst Target Price Adjustment by JP Morgan | IQV Stock News - GuruFocus
IQV Q1 Earnings Call: Real-World Evidence Drives Outperformance Amid Sector Uncertainty - Yahoo Finance
IQVIA Holdings (NYSE:IQV) Partners With SCRI Innovations To Enhance Global Oncology Trials - Yahoo
IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials - marketscreener.com
IQVIA Teams Up With SCRI to Expedite Development of New Cancer Therapies - marketscreener.com
IQVIA And SCRI Collaborate To Accelerate Global Oncology Trials - marketscreener.com
Is IQVIA Holdings Inc. (IQV) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey
Deep Dive Into IQVIA Hldgs Stock: Analyst Perspectives (10 Ratings) - Benzinga
IQVIA Holdings (IQV): Analyst Maintains Rating, Lowers Price Tar - GuruFocus
IQVIA Holdings (IQV): Analyst Maintains Rating, Lowers Price Target | IQV Stock News - GuruFocus
Mizuho Adjusts Price Target for Iqvia (IQV) to $190 | IQV Stock News - GuruFocus
Mizuho Adjusts Price Target on IQVIA Holdings to $190 From $210, Maintains Outperform Rating - marketscreener.com
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Questex’s Fierce Biotech Announces 2025 Fierce CRO Award Finalists - GlobeNewswire Inc.
Positive Outlook for IQVIA Holdings Driven by Resilient TAS, Strategic Capital Allocation, and R&D Strength - TipRanks
IQVIA Holdings Inc. (NYSE:IQV) Q1 2025 Earnings Call Transcript - MSN
IQVIA at BofA Securities 2025: Strong Q1 Amid Market Challenges By Investing.com - Investing.com Nigeria
IQVIA at BofA Securities 2025: Strong Q1 Amid Market Challenges - Investing.com
Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends - Yahoo Finance
(IQV) Investment Analysis and Advice - news.stocktradersdaily.com
IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates - MSN
IQVIA: Q1 Earnings Support Steady Optimism (NYSE:IQV) - Seeking Alpha
IQVIA raises 2025 revenue guidance amid strong TAS growth and expanded AI deployment - MSN
Morgan Stanley Adjusts Price Target on IQVIA Holdings to $185 From $250, Maintains Overweight Rating - marketscreener.com
Truist Financial Sticks to Its Buy Rating for IQVIA Holdings (IQV) - The Globe and Mail
IQVIA Ups Revenue Forecast After Exceeding Profit Estimates - Finimize
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13 - Business Wire
Barclays Lowers IQVIA Holdings (IQV) Price Target to $165 Amid Demand Concerns | IQV stock price - paginasiete.bo
IQVIA (IQV) Target Price Lowered by UBS, Rating Maintained | IQV Stock News - GuruFocus
IQVIA Holdings (IQV): Barclays Lowers Price Target to $165 | IQV Stock News - GuruFocus
Stephens Adjusts Price Target on IQVIA Holdings to $200 From $250, Maintains Overweight Rating - marketscreener.com
Citigroup Adjusts Price Target on IQVIA Holdings to $160 From $210, Maintains Neutral Rating - marketscreener.com
Baird Adjusts Price Target on IQVIA Holdings to $161 From $195, Maintains Neutral Rating - marketscreener.com
Barclays Adjusts Iqvia (IQV) Price Target Amid Demand Concerns | IQV Stock News - GuruFocus
IQVIA reports first-quarter 2025 results - IQVIA
IQVIA Holdings Inc (IQV) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
IQVIA Holdings Inc (IQV) Q1 2025 Earnings Call Highlights: Stron - GuruFocus
IQVIA: Q1 Earnings Snapshot - CTPost
Decoding IQVIA Holdings Inc (IQV): A Strategic SWOT Insight - GuruFocus
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):